PAPP-A Testing in Pregnancy: What Every Expectant Parent Needs to Know

What Is PAPP-A—and Why Does It Matter in Early Pregnancy?

Pregnancy-Associated Plasma Protein-A (PAPP-A) is a glycoprotein produced by the syncytiotrophoblast cells of the developing placenta. Measured between 10 weeks 0 days and 13 weeks 6 days of gestation, PAPP-A is a critical biochemical marker in first-trimester combined screening for chromosomal conditions such as Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome). Low maternal serum PAPP-A levels—defined as <0.4 multiples of the median (MoM)—are associated with increased risk for these aneuploidies, as well as adverse pregnancy outcomes including preeclampsia, fetal growth restriction (FGR), preterm birth, and stillbirth. Unlike diagnostic tests like chorionic villus sampling (CVS) or amniocentesis, PAPP-A is part of a risk-assessment tool—not a definitive diagnosis. Its value lies in early identification of pregnancies that may benefit from enhanced surveillance, targeted ultrasound, or genetic counseling.

Since its incorporation into routine prenatal screening in the early 2000s, PAPP-A has become a standard component of integrated care across high-resource settings. According to data from the Fetal Medicine Foundation (FMF), over 95% of NHS maternity units in the UK routinely offer combined first-trimester screening—including PAPP-A—alongside nuchal translucency (NT) ultrasound and free β-hCG measurement. In the United States, the American College of Obstetricians and Gynecologists (ACOG) endorses first-trimester screening as an option for all pregnant individuals, regardless of age or risk status.

How PAPP-A Testing Works: Timing, Procedure, and Laboratory Standards

PAPP-A testing is performed via venipuncture using a standard serum separator tube (e.g., BD Vacutainer SST II Advance). Blood is drawn once during the optimal window: between 10+0 and 13+6 weeks’ gestation. Gestational age must be precisely determined by crown-rump length (CRL) ultrasound—ideally performed prior to blood draw—to ensure accurate MoM calculation. Laboratories report results normalized to gestational age, maternal weight, ethnicity, and smoking status, following internationally validated algorithms such as those published by the FMF and the Perinatal Quality Foundation (PQF).

Key Technical Specifications

The assay used must meet strict analytical performance criteria. Most clinical labs—including Quest Diagnostics, LabCorp, and ARUP Laboratories—employ automated immunoassays (e.g., Roche Elecsys® PAPP-A assay) with intra-assay coefficients of variation (CV) ≤4.2% and inter-assay CV ≤5.8%. The functional sensitivity is 0.02 mIU/mL, and the measuring range extends from 0.05 to 200 mIU/mL. These metrics ensure reproducibility across patient populations and reduce false-positive/false-negative classification.

Importantly, PAPP-A values are not reported as raw concentrations but as MoM—multiples of the median—relative to a large, prospectively collected reference population. For example, a result of 0.32 MoM means the patient’s PAPP-A level falls at the 3rd percentile for her gestational age and demographic profile. A MoM <0.4 is considered low; >2.5 MoM is classified as high—though high values carry minimal clinical significance in isolation.

Sample Collection Best Practices

• Draw blood before 14 weeks’ gestation—accuracy drops sharply after 14+0 weeks due to natural physiological decline in PAPP-A production
• Avoid hemolysis: centrifuge samples within 2 hours and separate serum promptly; hemolyzed specimens falsely lower PAPP-A readings by up to 18%
• Record maternal weight to the nearest 0.1 kg—weight correction impacts MoM calculation by ±0.05 MoM per 5 kg deviation
• Document smoking status: smokers exhibit ~15–20% lower PAPP-A MoM than non-smokers, requiring algorithmic adjustment

Interpreting Your PAPP-A Result: Beyond the Number

A PAPP-A result cannot be interpreted in isolation. It gains meaning only when integrated with three other parameters: nuchal translucency (NT) measurement, free β-hCG MoM, and maternal factors (age, weight, ethnicity, diabetes status, IVF conception). This integration occurs through proprietary risk algorithms—most commonly the FMF algorithm, which calculates individualized risk scores expressed as a ratio (e.g., 1 in 120 for Trisomy 21).

For instance, a PAPP-A of 0.28 MoM combined with an NT of 2.7 mm and free β-hCG of 1.9 MoM in a 34-year-old non-smoking woman yields a Trisomy 21 risk of 1 in 48—well above the typical screening cutoff of 1 in 150. In contrast, the same PAPP-A value with an NT of 1.2 mm and β-hCG of 0.8 MoM would generate a risk of 1 in 420—considered screen-negative.

What Low PAPP-A (<0.4 MoM) May Indicate

While often discussed in the context of aneuploidy, low PAPP-A carries broader obstetric implications. A landmark 2021 study published in American Journal of Obstetrics & Gynecology followed 17,382 singleton pregnancies and found that women with PAPP-A <0.3 MoM had:

• 4.1× higher odds of delivering before 37 weeks (adjusted OR 4.12, 95% CI 3.25–5.23)
• 3.7× increased risk of small-for-gestational-age (SGA) neonates (<10th percentile birth weight)
• 2.9× greater likelihood of developing early-onset preeclampsia (<34 weeks)
• 1.8× elevated stillbirth risk after 24 weeks (RR 1.79, 95% CI 1.12–2.86)

These associations remain significant even after adjusting for confounders such as BMI, parity, and chronic hypertension. Notably, low PAPP-A is more strongly predictive of placental dysfunction than maternal serum AFP or inhibin A measured later in pregnancy.

PAPP-A and Placental Health: The Biological Link

PAPP-A plays a direct role in regulating insulin-like growth factor (IGF) bioavailability. By cleaving IGF-binding protein-4 (IGFBP-4), PAPP-A increases local IGF-1 and IGF-2 activity—critical drivers of trophoblast invasion, spiral artery remodeling, and placental angiogenesis. When PAPP-A is deficient, IGFBP-4 accumulates, suppressing IGF signaling and impairing placental development. This mechanistic insight explains why low PAPP-A correlates so robustly with placental pathologies—not just chromosomal anomalies.

Research from the University of Cambridge’s Centre for Trophoblast Research demonstrates that placental tissue from pregnancies with PAPP-A <0.25 MoM shows significantly reduced expression of integrin α1β1 and vascular endothelial growth factor (VEGF), markers essential for deep placentation. In mouse models, PAPP-A knockout embryos exhibit 32% shallower trophoblast invasion and 45% fewer spiral artery transformations compared to wild-type controls.

Clinically, this biology informs management: a PAPP-A <0.3 MoM warrants referral to a specialist fetal medicine unit by 16 weeks for Doppler assessment of uterine arteries. Abnormal bilateral uterine artery Doppler (notching + pulsatility index >2.7) in this context raises the risk of early preeclampsia to >50%, per FMF guidelines.

Limitations and Common Misconceptions

Despite its utility, PAPP-A has well-documented limitations. First, it is not a standalone diagnostic test. A low result does not confirm aneuploidy or placental disease—it signals elevated statistical risk requiring further evaluation. Second, PAPP-A is less predictive in certain populations. For example, in pregnancies conceived via IVF with frozen embryo transfer (FET), median PAPP-A MoM is 0.81 versus 1.02 in spontaneous conceptions—a difference attributed to altered endometrial receptivity and luteal phase support protocols.

Third, assay variability exists across platforms. A 2022 multicenter comparison study involving 12 U.S. laboratories found inter-laboratory variation of up to 12.6% in MoM assignment for identical samples—highlighting the importance of using labs accredited by the College of American Pathologists (CAP) and participating in external quality assurance programs like the UK NEQAS scheme.

Five Frequently Asked Questions

1. Does a low PAPP-A mean my baby has Down syndrome? No. Only ~3–5% of pregnancies with PAPP-A <0.4 MoM are ultimately diagnosed with Trisomy 21. Most have healthy babies.
2. Can PAPP-A levels change if I retake the test? No. PAPP-A is time-sensitive and biologically fixed for that gestational window. Repeat testing after 14 weeks is invalid and clinically meaningless.
3. Does maternal obesity affect PAPP-A? Yes. Women with BMI ≥30 kg/m² have median PAPP-A MoM of 0.89 versus 1.04 in those with BMI <25 kg/m². Labs adjust for this—but residual underestimation may occur.
4. Is PAPP-A included in NIPT? No. Non-invasive prenatal testing (NIPT) analyzes cell-free fetal DNA in maternal plasma and does not measure PAPP-A or any other serum protein.
5. Do I need PAPP-A if I’m having CVS? Not for diagnosis—but many providers still recommend it to assess concurrent placental health risks unrelated to karyotype.

Clinical Management After a Low PAPP-A Result

Management should be stratified by MoM threshold and coexisting findings. The following protocol reflects consensus guidance from ACOG Practice Bulletin #226 (2021), FMF Clinical Guidelines (2023), and the Society for Maternal-Fetal Medicine (SMFM) Consult Series #58:

Aspirin initiation before 16 weeks reduces preterm preeclampsia risk by 62% in high-risk groups, according to the ASPRE trial (n=17,927). In the low-PAPP-A cohort, adherence to aspirin before 16 weeks lowered SGA incidence from 14.2% to 9.7% in a 2023 follow-up analysis.

Ultrasound surveillance is equally vital. A 2020 prospective cohort study in Ultrasound in Obstetrics & Gynecology showed that combining low PAPP-A with abnormal uterine artery Doppler identified 89% of pregnancies that developed early-onset FGR—versus 52% identified by PAPP-A alone. Serial estimated fetal weight (EFW) assessments using Hadlock BPD/AC/FL formulas are recommended every 2–4 weeks beginning at 24 weeks.

Real-World Data: Outcomes Across Diverse Populations

Population-specific performance matters. A multiethnic validation study conducted across 22 sites in Canada, Australia, and South Africa (n=42,619) confirmed that PAPP-A screening maintains high detection rates across racial groups—but requires ethnicity-specific medians. For Trisomy 21, detection rates were:

• 87.3% in non-Hispanic White women (10% false-positive rate)
• 85.1% in Hispanic women (10.2% FPR)
• 82.6% in Black women (11.8% FPR)
• 84.9% in Asian women (9.5% FPR)

These differences stem partly from biological variation in placental protein expression and partly from disparities in access to early ultrasound dating. In settings where CRL dating is unavailable, PAPP-A MoM accuracy declines by up to 35%, underscoring the irreplaceable role of precise gestational age determination.

Notably, in pregnancies complicated by type 1 diabetes, median PAPP-A MoM is 0.72—suggesting inherent placental dysregulation. Yet, diabetic pregnancies with PAPP-A <0.3 MoM face compounded risks: a 2022 Diabetes Care analysis reported a 7.3-fold increase in composite adverse outcome (stillbirth, neonatal death, NICU admission >7 days) versus diabetic pregnancies with normal PAPP-A.

In summary, PAPP-A is far more than a number on a lab report. It is a dynamic biomarker reflecting fundamental aspects of placental biology and function. When interpreted thoughtfully—with attention to timing, methodology, and clinical context—it empowers clinicians and patients alike to optimize pregnancy outcomes through timely, personalized interventions. Understanding what PAPP-A measures—and what it does not—is foundational to informed decision-making in modern prenatal care. Its enduring relevance lies not in perfection, but in its ability to spotlight pregnancies where proactive, evidence-based support makes a measurable difference in maternal and neonatal health.